Portfolio – Q217

My portfolio (at cost) of S’pore stocks for Q217 close,

Note : Stocks are arranged in descending order of % holdings

 
Summary
The STI closed at 3,226.48, +12% from end 2016. Using cost as a reference, my portfolio stats (vs 2016),

• Size (Stocks Only) : +4.71% (Cost) / +11.6% (Market Value)
  
• Portfolio Performance (Includes Cash) vs End-2016 Mkt Value : 3.8% (Unrealised) + 0.52% (Realised) + 1.69% (Div) = +6.02%
  
• Further Breakdown of Realised P&L : +0.34% (Stocks Bought before 2017) + 0.19% (Stocks Bought in 2017)
  

So, +6.02% vs +12% (STI), half the performance of STI!

For Q2, I continued to reduce my transaction volume. Many of my old favourites (Yieldstocks & REITs) are facing declining profits and despite lower prices, the Risk-Reward do not look attractive yet. Further, with STI hitting higher and not seeing the same for our economy, I continue to stay on the defensive.

For Q3, I plan to continue with my defensive approach and continue to sell into strength. My longer term hold counters continue to be KIT, FCOT and RafflesMed. REITs have done well in 2017 and I may be looking at some of the laggards eg CMT, SPHREIT, bearing in mind there must be a reason why they are lagging the rest eg. non-Growth.

Portfolio Changes (vs Q416)

• New Additions : —
  
• Increases : RafflesMed
  
• Decreases : FCOT, M1
  
• No Change : SingPost, Kingsmen, King Wan, F&N, Genting, Starhub, KIT
  
• No More : —
  
  

Exchange Rates (for Q217)

• IDR (Indonesia Rupiah) -1.7% : LMIR – Continued to weaken, -3.96% for the year
  
• AUD (Australia $) -1.2% : AusNet, A-HTrust, Singtel, FLT – Still +1% for the year
  
• JPY (Japanese Yen) -1.86% : Weakened for Q2, -1.36% for the year. LDP losing seats, politically not as stable. But, CRT just rx G.O.